Exact Sciences Reinforces Its Market Edge With Strategic Alliances & Profit Growth! 

Exact Sciences Corporation reported its financial results for the second quarter of 2025. The company delivered strong performance metrics and revised its financial guidance upward, reflecting solid growth across its operations. Exact Sciences processed a record 1.3 million test results during the quarter, which contributed to a 16% yearover-year increase in core revenue. The company’s adjusted EBITDA also rose significantly to an all-time high of $138 million, marking a 26% increase from the previous year. Despite these accomplishments, the company reported a GAAP net loss of $1 million owing to one-time costs of $15 million associated with efficiency and productivity improvements.